| Mark G Schwei, MD | |
|
2870 E Live Oak Cir, Holladay, UT 84117-5544 | |
| (801) 870-9746 | |
| Not Available |
| Full Name | Mark G Schwei |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Child & Adolescent Psychiatry |
| Location | 2870 E Live Oak Cir, Holladay, Utah |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639199110 | NPI | - | NPPES |
| Entity Name | Multicare Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497766638 PECOS PAC ID: 7719899897 Enrollment ID: O20031105000760 |
News Archive
Stroke treatments and prevention to improve quality of life for people who experience a stroke is poorer than researchers hoped, with stroke still taking nearly three out of five quality years off a person's life, according to a new study published in the October 9, 2013, online issue of Neurology, the medical journal of the American Academy of Neurology.
In a new study recently published in the journal Science, a team of researchers in the U.S. found that most of the antibodies circulating in the blood target areas of the viral spike protein outside the receptor-binding domain (RBD), the part of the spike that binds directly to human cell receptors.
Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced top-line results from two Phase 2 clinical studies of Z160 in chronic pain indications.
Washington Research Foundation is helping University of Washington clinicians and researchers —one a MacArthur Fellow — to develop BiliCam, an iPhone app that can help determine the severity of jaundice in a newborn without having to draw blood.
› Verified 6 days ago
| Entity Name | Peacehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134178999 PECOS PAC ID: 9739092065 Enrollment ID: O20031111000831 |
News Archive
Stroke treatments and prevention to improve quality of life for people who experience a stroke is poorer than researchers hoped, with stroke still taking nearly three out of five quality years off a person's life, according to a new study published in the October 9, 2013, online issue of Neurology, the medical journal of the American Academy of Neurology.
In a new study recently published in the journal Science, a team of researchers in the U.S. found that most of the antibodies circulating in the blood target areas of the viral spike protein outside the receptor-binding domain (RBD), the part of the spike that binds directly to human cell receptors.
Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced top-line results from two Phase 2 clinical studies of Z160 in chronic pain indications.
Washington Research Foundation is helping University of Washington clinicians and researchers —one a MacArthur Fellow — to develop BiliCam, an iPhone app that can help determine the severity of jaundice in a newborn without having to draw blood.
› Verified 6 days ago
| Entity Name | Peacehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720056187 PECOS PAC ID: 5890689293 Enrollment ID: O20040209000272 |
News Archive
Stroke treatments and prevention to improve quality of life for people who experience a stroke is poorer than researchers hoped, with stroke still taking nearly three out of five quality years off a person's life, according to a new study published in the October 9, 2013, online issue of Neurology, the medical journal of the American Academy of Neurology.
In a new study recently published in the journal Science, a team of researchers in the U.S. found that most of the antibodies circulating in the blood target areas of the viral spike protein outside the receptor-binding domain (RBD), the part of the spike that binds directly to human cell receptors.
Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced top-line results from two Phase 2 clinical studies of Z160 in chronic pain indications.
Washington Research Foundation is helping University of Washington clinicians and researchers —one a MacArthur Fellow — to develop BiliCam, an iPhone app that can help determine the severity of jaundice in a newborn without having to draw blood.
› Verified 6 days ago
| Entity Name | Peacehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609061969 PECOS PAC ID: 8820178288 Enrollment ID: O20080110000429 |
News Archive
Stroke treatments and prevention to improve quality of life for people who experience a stroke is poorer than researchers hoped, with stroke still taking nearly three out of five quality years off a person's life, according to a new study published in the October 9, 2013, online issue of Neurology, the medical journal of the American Academy of Neurology.
In a new study recently published in the journal Science, a team of researchers in the U.S. found that most of the antibodies circulating in the blood target areas of the viral spike protein outside the receptor-binding domain (RBD), the part of the spike that binds directly to human cell receptors.
Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced top-line results from two Phase 2 clinical studies of Z160 in chronic pain indications.
Washington Research Foundation is helping University of Washington clinicians and researchers —one a MacArthur Fellow — to develop BiliCam, an iPhone app that can help determine the severity of jaundice in a newborn without having to draw blood.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark G Schwei, MD 2870 E Live Oak Cir, Holladay, UT 84117-5544 Ph: (801) 870-9746 | Mark G Schwei, MD 2870 E Live Oak Cir, Holladay, UT 84117-5544 Ph: (801) 870-9746 |
News Archive
Stroke treatments and prevention to improve quality of life for people who experience a stroke is poorer than researchers hoped, with stroke still taking nearly three out of five quality years off a person's life, according to a new study published in the October 9, 2013, online issue of Neurology, the medical journal of the American Academy of Neurology.
In a new study recently published in the journal Science, a team of researchers in the U.S. found that most of the antibodies circulating in the blood target areas of the viral spike protein outside the receptor-binding domain (RBD), the part of the spike that binds directly to human cell receptors.
Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced top-line results from two Phase 2 clinical studies of Z160 in chronic pain indications.
Washington Research Foundation is helping University of Washington clinicians and researchers —one a MacArthur Fellow — to develop BiliCam, an iPhone app that can help determine the severity of jaundice in a newborn without having to draw blood.
› Verified 6 days ago
Dr. Adam Phillip Pendleton, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 6550 S Millrock Dr Ste 125, Holladay, UT 84121 Phone: 801-821-2333 Fax: 801-901-1194 | |
Steven Vincent Teynor, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 6550 S Millrock Dr Ste 125, Holladay, UT 84121 Phone: 801-821-2333 Fax: 801-901-1194 | |
Patricia P Cardenas-wallenfelt, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2290 E. 4500 So., Suite 215, Holladay, UT 84117 Phone: 801-274-3625 |